CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD

Blood

Volumn 101, Issue 10, 2003, Pages 4033-4041

  Nicolaou, Fotini ^b   Teodoridis, Jens M ^b   Park, Heiyoung ^b   Georgakis, Alexander ^b   Farokhzad, Omid C ^b   Böttinger, Erwin P ^b   Da Silva, Nicolas ^b   Rousselot, Philippe ^b   Chomienne, Christine ^b   Ferenczi, Katalin ^b   Arnaout, M Amin ^b   Shelley, C Simon ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR AP 1; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ENZYME INHIBITOR; GLYCOPROTEIN P 15095; LEUKOCYTE ANTIGEN; NITRILE;

ARTICLE; CD11C GENE; CELL TYPE; CONTROLLED STUDY; GENE; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; ONCOGENE D JUN; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; BINDING SITE; CELL CULTURE; CELL DIVISION; CELL STRAIN U937; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE; PATHOLOGY; PLASMID;

ANTIGENS, CD; ANTIGENS, CD11C; BASE SEQUENCE; BINDING SITES; BUTADIENES; CELL DIVISION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, JUN; GENES, RAS; HELA CELLS; HUMANS; LEUKEMIA, HAIRY CELL; MOLECULAR SEQUENCE DATA; NITRILES; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENES; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 0038639682     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0324     Document Type: Article

References (109)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609-630.
2. Schwarting R, Steln H, Wang CY. The monoclonal antibodies αS-HCL1 (αLeu-14) and αS-HCL3 (αLeu-M5) allow the diagnosis of hairy cell leukemia. Blood. 1985;65:974-983.
3. Golde DW, Stevens RH, Quan SG, Saxon A. Immunoglobulin synthesis in hairy cell leukemia. Brit J Haematol. 1977;35:359-365.
4. Saxon A, Stevens RH, Golde DW. T-lymphocyte variant of hairy-cell leukemia. Ann Int Med. 1978;88:323-326.
5. Arnaout MA. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood. 1990;75:1037-1050.
6. Ogura M, Morishima Y, Ohno R, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood. 1985;66:1384-1392.
7. Faguet GB, Satya-Prakash KL, Agee JF. Cytochemical, cytogenetic, immunophenotypic and tumorigenic characterization of two hairy cell lines. Blood. 1988;71:422-429.
8. Shelley CS, Farokhzad OC, Arnaout MA. Identification of cell-specific and developmentally regulated nuclear factors that direct myeloid and lymphoid expression of the CD11a gene. Proc Natl Acad Sci U S A. 1993;90;5364-5368.
9. López-Cabrera M, Nueda A, Vara A, Garcia-Agullar J, Tugores A. Corbí AL. Characterization of the p150,95 leukocyte integrin α subunit (CD11c) gene promoter. J Biol Chem. 1993;268:1187-1193.
10. Potter H, Weir L, Leder P. Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci U S A. 1984;81:7161-7165.
11. Shelley CS, Arnaout MA. The promoter of the CD11b gene directs myeloid-specific and developmentally regulated expression. Proc Natl Acad Sci U S A. 1991;88:10525-10529.
12. Farokhzad OC, Shelley CS, Arnaout MA. Induction of the CD11b gene during activation of the monocytic cell line U937 requires a novel nuclear factor MS-2. J Immunol. 1996;157:5597-5605.
13. Saxon A, Stevens RH, Golde DW. T-lymphocyte varient of hairy-cell leukemia. Ann Intern Med. 1978;88:323-326.
14. Saxon A, Stevens RH, Quan SG, Golde DW. Immunologic characterization of hairy cell leukemias in continuous culture. J Immunol. 1978;120:777-782.
15. Noti JD, Reinemann BC, Petrus MN. Sp1 binds two sites in the CD11c promoter in vivo specifically in myeloid cells and cooperates with AP1 to activate transcription. Mol Cell Biol. 1996;16:2940-2950.
16. López-Rodríguez C, Chen H-M, Tenen DG, Corbí AL. Identification of Sp1-binding sites in the CD11c (p150,95α) and CD11a (LFA-1α) integrin subunit promoters and their involvement in the tissue-specific expression of CD11c. Eur J Immunol. 1995;25:3496-3503.
17. Noti JD. Sp3 mediates transcriptional activation of the leukocyte integrin genes CD11C and CD11B and cooperates with c-Jun to activate CD11C. J Biol Chem. 1997;272:24038-24045.
18. Farokhzad OC, Teodoridis JM, Park H, Arnaout MA, Shelley CS. CD43 gene expression is mediated by a nuclear factor which binds pyrimidine-rich single-stranded DNA. Nucleic Acids Res. 2000;28:2256-2267.
19. 2 integrin gene promoter. J Immunol. 2002;168:3887-3893.
20. Karim FD, Urness LD, Thummel CS, et al. The ETS domain: a new DNA-binding motif that recognizes a purine-rich core DNA sequence. Genes Dev. 1990;4:1451-1453.
21. Rubio MA, López-Rodríguez C, Nueda A, et al. Granulocyte-macrophage colony-stimulating factor, phorbol ester, and sodium butyrate induce the CD11c integrin gene promoter activity during myeloid cell differentiation. Blood. 1995;86:3715-3724.
22. Lassar AB, Buskin JN, Lockshon D, et al. MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. Cell. 1989;58:823-831.
23. López-Rodríguez C, Kluin-Nelemans HC, Corbí AL. AP-1 regulates the basal and developmentally induced transcription of the CD11c leukocyte integrin gene. J Immunol. 1996;156:3780-3787.
24. Aragonés J, López-Rodríguez C, Corbí A, et al. Dithiocarbamates trigger differentiation and induction of CD11c gene through AP-1 in the myeloid lineage. J Biol Chem. 1996;271:10924-10931.
25. Noti JD, Reinemann BC, Petrus MN. Regulation of the leukocyte integrin gene CD11c is mediated by AP1 and Ets transcription factors. Mol Immunol. 1996;33:115-127.
26. Vivanco Ruiz MdM, Bugge TH, Hirschmann P, Stunnenberg HG. Functional characterization of a natural retinoic acid responsive element. EMBO J. 1991;10:3829-3838.
27. Corbí AL, López-Rodríguez C. CD11c integrin gene promoter activity during myeloid differentiation. Leuk Lymphoma. 1997;25:415-425.
28. López-Rodríguez C, Corbí AL, PU.1 negatively regulates the CD11c integrin gene promoter through recognition of the major transcriptional start site. Eur J Immunol. 1997;27:1843-1847.
29. Smale ST, Baltimore D. The initiator as a transcriptional control element. Cell. 1989;57:103-113.
30. Weis L, Reinberg D. Transcription by RNA polymerase II: initiator-directed formation of transcription-competent complexes. FASEB J. 1992;6:3300-3309.
31. Akira S, Isshiki H, Sugita T, et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 1990;9:1897-1906.
32. Pearse RN, Feinman R, Shuai K, Darnell JE Jr, Ravetch JV. Interferon γ-induced transcription of the high-affinity Fc receptor for IgG requires assembly of a complex that includes the 91-kDa subunit of transcription factor ISGF3. Proc Natl Acad Sci U S A. 1993;90:4314-4318.
33. Graf T. Myb: a transcriptional activator linking proliferation and differentiation. Curr Opin Genet Dev. 1992;2:249-255.
34. Brown PH, Alani P, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene. 1993;8:877-886.
35. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB mouse epidermal cells. Proc Natl Acad Sci U S A. 1994;91:609-613.
36. Felg LA, Cooper GM. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol Cell Biol. 1988;8:3235-3243.
37. Berger I, Shaul Y, The human junD gene is positively and selectively autoregulated. DNA Cell Biol. 1994;13:249-255.
38. Sweet RW, Yokoyama S, Kamata T, Feramisco JR, Rosenberg M, Gross M. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature. 1984;311:273-275.
39. Karin M, Liu ZG, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 1997;9:240-246.
40. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over.' Trends Cell Biol. 2000;10:147-154.
41. Avruch J, Khokhlatchev A, Kyrlakis JM, et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res. 2001;56:127-155.
42. Kerkhoff E, Rapp UR. The Ras-Raf relationship: an unfinished puzzle. Adv Enzyme Regul. 2001;41:261-267.
43. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227-238.
44. Jun T, Gjoerup O, Roberts TM. Tangled webs: evidence of cross-talk between c-Raf-1 and Akt. Sci STKE. 1999;1999:PE1.
45. Feig LA, Urano T, Cantor S. Evidence for a Ras/Raf signaling cascade. Trends Biochem Sci. 1996;21:438-441.
46. Wolthuis RM, Bos JL. Ras caught in another affair: the exchange factors for Ral. Curr Opin Genetic Dev. 1999;9:112-117.
47. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273:18623-18632.
48. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976;17:565-577.
49. Shauiian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20:2390-2400.
50. Heintz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and C-jun expression by asbestos. Proc Natl Acad Sci U S A. 1993;90:3299-3303.
51. Yamanishi DT, Buckmeier JA, Meyskens FL Jr. Expression of c-jun, jun-B, and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas. J Invest Dermatol. 1991;97:349-353.
52. Fujimoto M, Sheridan PJ, Sharp ZD, Weaker FJ, Kagan-Hallet KS, Story JL. Proto-oncogene analysis in brain tumors. J Neurosurg. 1989;70:910-915.
53. Neyns B, Katesuwanasing D, Vermeij J, et al. Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Oncogene. 1996;12:1247-1257.
54. Miller AD, Curran T, Verma IM. c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. Cell. 1984;36:51-60.
55. Lee WMF, Lin C, Curran T. Activation of the transforming potential of the human fos proto-oncogene requires message stabilization and results in increased amounts of partially modified fos protein. Mol Cell Biol. 1988;8:5521-5527.
56. Raymond V, Atwater JA, Verma IM. Removal of an mRNA destabilizing element correlates with the increased oncogenicity of proto-oncogene fos. Oncogene Res. 1989;5:1-12.
57. Schütte J, Minna JD, Birrer MJ. Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms Rat-1a cells as a single gene. Proc Natl Acad Sci U S A. 1989;86:2257-2261.
58. Schütte J, Viallet J, Nau M, Segal S, Fedorko J, Minna JD. jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun. Cell. 1989;59:987-997.
59. Abate C, Patel L, Rauscher FJ III, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science. 1990;249:1157-1161.
60. Boyle WJ, Smeal T, Defize LHK, et al. Activation of protein kinase C decreases phosphorylation of c-jun at sites that negatively regulate its DNA-binding activity. Cell. 1991;64:573-584.
61. Van Beveren C, Van Straaten F, Curran T, Méller R, Verma IM. Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell. 1983;32:1241-1255.
62. Van Beveren C, Enami S, Curran T, Verma IM. FBR murine osteosarcoma virus, II: nucleotide sequence of the provirus reveals that the genome contains sequences acquired from two cellular genes. Virology. 1984;135:229-243.
63. Nishizawa M, Goto N, Kawal S. An avian transforming retrovirus isolated from a nephroblastoma that carries the fos gene as the oncogene. J Virol. 1987;61:3733-3740.
64. Maki Y, Bos TJ, Davis C, Starbuck M, Vogt PK. Avian sarcoma virus 17 carries the jun oncogene. Proc Natl Acad Sci U S A. 1987;84:2848-2852.
65. Forrest D, Curran T. Crossed signals: oncogenic transcription factors. Curr Opin Genet Dev. 1992;2:19-27.
66. Curran T, Miller AD, Zokas L, Verma IM. Viral and cellular fos proteins: a comparative analysis. Cell. 1984;36:259-268.
67. Curran T, Van Beveren C, Ling N, Verma IM. Viral and cellular fos proteins are complexed with a 39,000-dalton cellular protein. Mol Cell Biol. 1985;5:167-172.
68. Kameda T, Akahori A, Sonobe MH, Suzuki T, Endo T, Iba H. JunD mutants with spontaneously acquired transforming potential have enhanced transactivating activity in combination with Fra-2. Proc Natl Acad Sci U S A. 1993;90:9369-9373.
69. Qin J-Z, Dummer R, Burg G, Döbbeling U. Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells. Blood. 1999;93:260-267.
70. Mori N, Fujii M, Iwal K, et al. Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells. Blood. 2000;95:3915-3921.
71. Blayney DW, Jaffe ES, Blattner WA, et al. The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphoma. Blood. 1983;62:401-405.
72. Naelm F, Capostagno VJ, Johnson CE Jr, Lehrer R, Gatti RA. Sézary syndrome: tartrate-resistant acid phosphatase in the neoplastic cells. Am J Clin Pathol. 1979;71:528-533.
73. Usui T, Konishi H, Sawada H, Uchino H. Existence of tartrate-resistant acid phosphatase activity in differentiated lymphoid leukemic cells. Am J Hematol. 1982;12:47-54.
74. Gallo RC. Kaplan memorial lecture: the family of human lymphotropic retroviruses called HTLV: HTLV-I in adult T-cell leukemia (ATL), HTLV-II in hairy cell leukemias, and HTLV-III in AIDS. Princess Takamatsu Symp. 1984;15:13-38.
75. Wachsman W, Golde DW, Chen IS. Hairy cell leukemia and human T cell leukemia virus. Semin Oncol. 1984;11:446-450.
76. Clore LS Jr, Stafford CT. Chronic urticaria as a presenting sign of hairy cell leukemia. Allergy Asthma Proc. 1999;20:51-55.
77. Crump M, Sutton DM, Pantalony D. Sézary syndrome in a patient with hairy cell leukemia in remission. Cancer. 1991;68:829-833.
78. Zucker-Franklin D, Amorosi EL, Ritz ND. Evolution of Sézary syndrome in the course of hairy cell leukemia. Blood. 1982;59:1181-1190.
79. Demeter J, Paloczi K. Observations on the development of T-cell leukaemia in the patient successfully treated by interteron-α for typical hairy cell leukaemia (HCL). Leukemia. 1992;6:1235-1236.
80. Knecht H, Sarraj A, Delacretaz F, Bachmann E, Clement F. Genotypic and phenotypic evidence of T-cell leukemia in a patient successfully treated by interferon-α for typical hairy cell leukemia. Leukemia. 1991;5:1031-1036.
81. Paolini R, Poletti A, Ramazzina E, et al. Co-existence of cutaneous T-cell lymphoma and B hairy cell leukemia. Am J Hematol. 2000;64:197-202.
82. Dearden CE, Matutes E, Catovsky D. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies. Semin Oncol. 2000;27(2 suppl 5): 22-26.
83. Ho AD, Suclu S, Stryckmans P, et al. Pentostatin (Nipent) in T-cell malignancies: Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer. Semin Oncol. 2000;27(2 suppl 5):52-57.
84. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340:952-956.
85. Piro LD. 2-Chlorodeoxyadenosine treatment of lymphoid malignancies. Blood. 1992;79:843-845.
86. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-1121.
87. Angel P, Imagawa M, Chiu R, et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell. 1987;49:729-739.
88. Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM. Induction of proto-oncogene JUN/Ap-1 by serum and TPA. Nature. 1988;334:629-631.
89. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/Ap-1. Cell. 1988;55:875-885.
90. Wilson T, Treisman R. Removal of poly(A) and consequent degradation of c-fos mRNA facilitated by 3′ AU-rich sequences. Nature. 1988;336:396-399.
91. Nakamura T, Datta R, Kharbanda S, Kufe D. Regulation of jun and fos gene expression in human monocytes by the macrophage colony-stimulating factor. Cell Growth Differ. 1991;2:267-272.
92. Abate C, Luk D, Curran T. A ubiquitous nuclear protein stimulates the DNA-binding activity of fos and jun indirectly. Cell Growth Differ. 1990;1:455-462.
93. Abate C, Luk D, Gentz R, Rauscher FJ III, Curran T. Expression and purification of the leucine zipper and DNA-binding domains of Fos and Jun: both Fos and Jun contact DNA directly. Proc Natl Acad Sci U S A. 1990;87:1032-1036.
94. Xanthoudakis S, Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J. 1992;11:653-665.
95. Curran T, Morgan JI. Superinduction of c-fos by nerve growth factor in the presence of peripherally active benzodiazepines. Science. 1985;229:1265-1268.
96. Barber JR, Verma IM. Modification of fos proteins: phosphorylation of c-fos, but not v-fos, is stimulated by 12-tetradecanoyl-phorbol-13-acetate and serum. Mol Cell Biol. 1987;7:2201-2211.
97. Müller R, Bravo R, Müller D, Kurz C, Renz M. Different types of modification in c-fos and its associated protein p39: modulation of DNA binding by phosphoylation. Oncogene Res. 1987;2:19-32.
98. Franza BR Jr, Rauscher FJ III, Josephs SF, Curran T. The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites. Science. 1988;239:1150-1153.
99. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature. 1991;353:670-674.
100. Franklin CC, Sanchez V, Wagner F, Woodgett JR, Kraft AS. Phorbol ester-induced amino-terminal phosphorylation of human JUN but not JUNB regulates transcriptional activation. Proc Natl Acad Sci U S A. 1992;89:7247-7251.
101. Minden A, Lin A, McMahon M, et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science. 1994;266:1719-1723.
102. Coso OA, Chiariello M, Yu J-C, et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell. 1995;81:1137-1146.
103. Minden A, Lin A, Claret F-X, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell. 1995;81:1147-1157.
104. Hart MJ, Eva A, Zangrilli D, et al. Cellular transformation and guanine nucleotide exchange activity are catalyzed by a common domain on the dbl oncogene product. J Biol Chem. 1994;269:62-65.
105. Horii Y, Beeler JF, Sakaguchi K, Tachibana M, Miki T. A novel oncogene, ost, encodes a guanine nucleotide exchange factor that potentially links Rho and Rac signaling pathways. EMBO J. 1994;13:4776-4786.
106. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992;70:389-399.
107. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992;70:401-410.
108. Vandel L, Montreau N, Vial E, Pfarr CM, Binetruy B, Castellazzi M. Stepwise transformation of rat embryo fibroblasts: c-Jun, JunB, or JunD can cooperate with Ras for focus formation, but a c-Jun-containing heterodimer is required for immortalization. Mol Cell Biol. 1996;16:1881-1888.
109. Harvey WH, Harb OS, Kosak ST, Sheaffer JC, Lowe LR, Heerema NA. Interferon-alpha-2b downregulation of oncogenes H-ras, c-raf-2, c-kit, c-myc, c-myb and c-fos in ESKOL, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascade. Leuk Res. 1994;18:577-585.